All In Biotech

NDA 022250 · Merz

Ampyra

Dalfampridine · Oral · Potassium Channel Blocker

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Nov 18, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Jan 22, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

85

32 Phase 3, 10 recruiting

FAERS reports

71,576

20,310 serious, 1,771 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 16, 2026.

AMPYRA is indicated as a treatment to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed [see Clinical Studies (14) ]. AMPYRA ® (dalfampridine) is a potassium channel blocker indicated to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed ( 1 , 14 ).

Mechanism: The mechanism by which dalfampridine exerts its therapeutic effect has not been fully elucidated. Dalfampridine is a broad spectrum potassium channel blocker. In animal studies, dalfampridine has been shown to increase conduction of action potentials in demyelinated axons through inhibition of potassium channels.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • AMPYRA · DALFAMPRIDINE 10MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dalfampridine" as an intervention, any sponsor and status, largest first.

All 85 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • gait disturbance10,994
  • drug ineffective8,325
  • fall7,361
  • fatigue5,556
  • balance disorder4,909
  • multiple sclerosis relapse4,788
  • therapy cessation4,511
  • dizziness4,000
  • urinary tract infection3,747
  • condition aggravated3,514
  • asthenia3,471
  • insomnia3,311

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20061
20082
20096
2010686
2011837
20121,050
20131,618
20146,349
20157,532
201612,012
201710,164
201810,789
20197,166
20203,152
20212,695
20222,758
20232,247
2024992
2025748
2026772

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ampyra (Dalfampridine)

2024 spending

$40.3M

Beneficiaries

1,046

6,957 claims

Per beneficiary

$38,490

$69.40 per unit

View as table
YearSpending
2020$72,053,833
2021$55,939,976
2022$48,646,409
2023$44,351,232
2024$40,260,360

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 33 on PubMed

Sponsor: Merz

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.